TLX.AX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 12:19):

Stats
今日成交量	801 251
平均成交量	1.23M
市值	5.06B
EPS	$0 ( 2024-02-21 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	765.00
ATR14	$0.0130 (0.08%)

音量相关性

長: 0.18 (neutral)

短: -0.30 (neutral)

Signal:(51.935) Neutral

Telix Pharmaceuticals 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Telix Pharmaceuticals 相关性 - 货币/商品

0.72
( moderate )

0.69
( moderate )

0.00
( neutral )

0.50
( neutral )

-0.58
( weak negative )

Telix Pharmaceuticals 财务报表

Annual	2023
营收:	$496.66M
毛利润:	$308.50M (62.12 %)
EPS:	$0.0163

FY	2023
营收:	$496.66M
毛利润:	$308.50M (62.12 %)
EPS:	$0.0163

FY	2022
营收:	$160.10M
毛利润:	$29.34M (18.32 %)
EPS:	$-0.340

FY	2021
营收:	$4.90M
毛利润:	$2.35M (47.98 %)
EPS:	$-0.313

Financial Reports:

No articles found.

Telix Pharmaceuticals

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.